Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 14 November, 2000

XTL Biopharm Ltd

Re Alliance

XTL Biopharmaceuticals Limited
14 November 2000

XTL Biopharmaceuticals Ltd.               Pharming Group N.V.

Kiryat Weizmann                           P.O. Box 451

P.O. Box 370, Rehovot 76100, Israel       2300 AL Leiden, The Netherlands

Tel: 972 8 9405 134                       Tel: +31 71 524 74 00

Fax: 972 8 9405 017                       Fax: +31 71 521 65 07                  

For Immediate Release

                                 HEPATITIS C

   -Agreement between XTL and Pharming Designed to Evaluate and Potentially
        Co-Develop Biopharmaceutical Protein for Use in Treating HCV-

Leiden, The Netherlands, Rehovot, Israel and New Ipswich, NH, November 14,
2000 - XTL Biopharmaceuticals Ltd. ('XTL') (LSE: XTL) and Pharming Group N.V.
('Pharming') (EASDAQ: PHAR and AEX: PHAR) today announced the signing of an
agreement to jointly evaluate and potentially co-develop recombinant human
Lactoferrin (rhLF) as a treatment for hepatitis C virus (HCV). Human
Lactoferrin is a natural protein with antibiotic, probiotic, anti-inflammatory
and immuno-modulating properties. Financial terms of the deal were not

'This agreement with Pharming represents XTL's most advanced stage partnership
to date and will provide depth to our increasing portfolio of potential
therapeutics to treat HCV,' stated Glenn Kazo, General Manager and Business
Officer of XTL Biopharmaceuticals Inc., based in the United States. 'We are
confident that this collaboration with Pharming, combined with XTL's
technology, will provide synergy to further develop our product pipeline.'

Pharming's President and CEO George J. M. Hersbach commented that: 'The
co-development agreement with XTL offers us the opportunity to combine our
technology with that of XTL's to evaluate and pursue the use of Pharming's
rhLF as a treatment for Hepatitis C, a serious chronic disease that affects a
rapidly increasing number of people worldwide.'

The development of Pharming's recombinant human Lactoferrin (rhLF) as a
potential treatment for infectious diseases is on track. Pharming successfully
completed a phase I clinical trial of intravenously administered rhLF that
demonstrated rhLF was well tolerated up to the highest dose of 60 mg/kg. This
excellent safety profile, combined with promising data from pre-clinical
studies, suggest that rhLF is a realistic therapeutic candidate for infectious
diseases, including HCV.

HCV is a major cause of chronic hepatitis in the United States and is a
leading cause for liver transplantation. The World Health Organization
estimates that 170 million people are infected with HCV worldwide,
approximately four million of whom are in the United States. Eighty five
percent of HCV infected persons will develop chronic hepatitis, of which 10-20
percent will progress to liver cirrhosis. The number of deaths attributable to
hepatitis C is expected to increase substantially in the next 10 to 20 years.

XTL Contacts:                                    Pharming Contacts:

Martin Becker, PhD, President and CEO            Rob Meines

Tel: +972 8 940 5134                             Praaning Meines Consultancy
Glenn Kazo, General Manager & Chief Business
Officer                                          Tel: +31 71 5247 429

Tel: +1 603 878 9857                             Tonua Fedusenko

David Yates / Sarah Mehanna                      KF Dunn & Associates

Financial Dynamics                               Tel: +1 302 328 3347

Tel: +44 (0) 20 7831 3113

Notes to Editors

Pharming Group

Pharming focuses on the development, production and commercialization of human
therapeutic proteins to be used in highly innovative therapies. Pharming has
developed a proprietary production platform of transgenic animals, capable of
producing human therapeutic proteins at high levels in their milk. Pharming's
product portfolio is aimed at treatments for genetic disorders, surgery and
trauma, infectious and inflammatory diseases, tissue and bone repair and
blood-related disorders. Pharming has operations in Belgium, Finland, the
Netherlands and the USA and currently employs more than 200 people.

XTL Biopharmaceuticals

XTL is developing therapeutics to treat hepatitis B, hepatitis C and other
infectious diseases using human monoclonal antibodies and synthetic chemical
products. XTL's competitive advantage lies in its proprietary Trimera
technology, which enables XTL to accelerate its internal product development
and to secure rights to drug candidates and other technology from third
parties. For more information about XTL, visit XTL's website at

For Pharming: The statements that are not historical facts contained in this
release are forward-looking statements and are made pursuant to the safe
harbor provisions of the Securities Litigation Reform Act of 1995. Such
statements involve risks and uncertainties that may differ materially from
those set forth in these statements. In addition, the economic, competitive,
governmental, technological and other factors identified in AVI's filings with
the Securities and Exchange Commission could affect such results.

                                    £ £ £


a d v e r t i s e m e n t